Patents by Inventor Matthew R. G. Taylor

Matthew R. G. Taylor has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Endothelin single nucleotide polymorphisms and methods of predicting ?-adrenergic receptor targeting agent efficacy
    Patent number: 10258606
    Abstract: The present invention concerns the use of methods for evaluating ?-adrenergic receptor targeting agent treatment for a patient, particularly one with a heart condition. In general, the disclosed methods entail determining the presence or absence of one or more polymorphisms in an endothelin gene system member. Based on the results of this determination, a ?-adrenergic receptor targeting agent may be prescribed, administered or a treatment regimen altered, including the administration of a ?-blocker. Accordingly, methods of treatment are also described.
    Type: Grant
    Filed: June 22, 2015
    Date of Patent: April 16, 2019
    Assignee: The Regents of the University of Colorado, A Body Corporate
    Inventors: Matthew R. G. Taylor, Luisa Mestroni
  • Endothelin Single Nucleotide Polymorphisms and Methods of Predicting B-Adrenergic Receptor Targeting Agent Efficacy
    Publication number: 20150366843
    Abstract: The present invention concerns the use of methods for evaluating ?-adrenergic receptor targeting agent treatment for a patient, particularly one with a heart condition. In general, the disclosed methods entail determining the presence or absence of one or more polymorphisms in an endothelin gene system member. Based on the results of this determination, a ?-adrenergic receptor targeting agent may be prescribed, administered or a treatment regimen altered, including the administration of a ?-blocker. Accordingly, methods of treatment are also described.
    Type: Application
    Filed: June 22, 2015
    Publication date: December 24, 2015
    Inventors: Matthew R.G. Taylor, Luisa Mestroni
  • Endothelin single nucleotide polymorphisms and methods of predicting ?-adrenergic receptor targeting agent efficacy
    Patent number: 9062347
    Abstract: The present invention concerns the use of methods for evaluating ?-adrenergic receptor targeting agent treatment for a patient, particularly one with a heart condition. In general, the disclosed methods entail determining the presence or absence of one or more polymorphisms in an endothelin gene system member. Based on the results of this determination, a ?-adrenergic receptor targeting agent may be prescribed, administered or a treatment regimen altered, including the administration of a ?-blocker. Accordingly, methods of treatment are also described.
    Type: Grant
    Filed: July 28, 2008
    Date of Patent: June 23, 2015
    Assignee: The Regents of the University of Colorado, a body corporate
    Inventors: Matthew R. G. Taylor, Luisa Mestroni
  • Endothelin Single Nucleotide Polymorphisms and Methods of Predicting B-Adrenergic Receptor Targeting Agent Efficacy
    Publication number: 20100298399
    Abstract: The present invention concerns the use of methods for evaluating ?-adrenergic receptor targeting agent treatment for a patient, particularly one with a heart condition. In general, the disclosed methods entail determining the presence or absence of one or more polymorphisms in an endothelin gene system member. Based on the results of this determination, a ?-adrenergic receptor targeting agent may be prescribed, administered or a treatment regimen altered, including the administration of a ?-blocker. Accordingly, methods of treatment are also described.
    Type: Application
    Filed: July 28, 2008
    Publication date: November 25, 2010
    Inventors: Matthew R. G. Taylor, Luisa Mestroni